| Unique ID issued by UMIN | UMIN000063705 |
|---|---|
| Receipt number | R000072851 |
| Scientific Title | Study on the efficacy and safety of Forel H tomy for drug-resistant epilepsy |
| Date of disclosure of the study information | 2026/11/20 |
| Last modified on | 2026/11/20 09:48:50 |
A study of the benefits and risks of using heat to treat a small area of the brain in people with epilepsy that does not respond to medicines
Forel-H-tomy for Epilepsy
Study on the efficacy and safety of Forel H tomy for drug-resistant epilepsy
Forel-H-tomy for Drug-Resistant Epilepsy
| Japan |
Drug-resistant epilepsy
| Neurosurgery | Adult |
Others
NO
To evaluate the safety and efficacy of radiofrequency thermocoagulation of the field of Forel (Forel-H-tomy) for drug-resistant epilepsy
Safety,Efficacy
Exploratory
Not applicable
Seizure freedom rate at 12 months after surgery.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Maneuver |
Participants undergo one session of stereotactic radiofrequency thermocoagulation of the field of Forel (Forel-H-tomy). A stereotactic frame is applied under local anesthesia, and the target is identified using MRI and CT. A lesioning electrode is inserted, and thermocoagulation is performed at 70 degrees for 40 seconds. The procedure takes approximately 30 minutes. Postoperative MRI is used to verify the lesion location and assess for hemorrhage.
| 20 | years-old | <= |
| 70 | years-old | >= |
Male and Female
1. Inpatients or outpatients at the Department of Neurosurgery, Tokyo Women's Medical University, with drug-resistant epilepsy diagnosed by an epilepsy specialist.
2. Failure to achieve at least 1 year of seizure control despite at least 2 years of treatment with adequate doses of two to three or more appropriate antiseizure medications, used as monotherapy or in combination, with seizures interfering with daily life.
3. Seizure onset clearly localized to one cerebral hemisphere based on clinical findings, electroencephalography, and neuroimaging.
4. Voluntary written informed consent provided by the participant after receiving an explanation of the study.
1. Current antiplatelet or anticoagulant treatment that cannot be interrupted.
2. Contraindication to MRI.
3. Pregnancy or breastfeeding.
4. Symptomatic hypotension or systolic blood pressure below 85 mmHg.
5. Deemed unsuitable for participation by the principal investigator.
15
| 1st name | Shiro |
| Middle name | |
| Last name | Horisawa |
Tokyo Women's Medical University
Department of Neurosurgery
162-8666
8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
neurosurgery0222@gmail.com
| 1st name | Shiro |
| Middle name | |
| Last name | Horisawa |
Tokyo Women's Medical University
Department of Neurosurgery
1580086
8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
neurosurgery0222@gmail.com
Tokyo Women's Medical University
Department of Neurosurgery
Self funding
Ethics Review Committee, Tokyo Women's Medical University
8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
rinri.bm@twmu.ac.jp
NO
| 2026 | Year | 11 | Month | 20 | Day |
Not publicly available
Partially published
https://doi.org/10.1002/epi4.12826
6
Six participants underwent unilateral Forel-H-tomy. At 12 months, 2/6 (33.3%) were seizure-free (Engel I), 2/6 had a seizure reduction of at least 50% (Engel III), and 2/6 were Engel IV. Persistent mild neurological adverse events occurred in 3/6. One participant was previously published as a case report.
| 2026 | Year | 11 | Month | 20 | Day |
Six participants with drug-resistant epilepsy were enrolled: four men and two women. Mean age at surgery was 65 years. All had focal to bilateral tonic-clonic seizures. Etiologies included intracerebral hemorrhage, ulegyria, hippocampal sclerosis, and acute subdural hematoma.
All six prospectively enrolled participants underwent unilateral Forel-H-tomy and were included in the clinical outcome analysis at 12 months.
At 12 months, three participants had persistent mild neurological adverse events: hypophonia in two and reduced manual dexterity in one. No life-threatening or fatal adverse events occurred.
At 12 months, the seizure freedom rate was 2/6 (33.3%). Two additional participants (2/6, 33.3%) had a seizure reduction of at least 50%. Engel outcomes were class I in two, class III in two, and class IV in two. Persistent mild neurological adverse events were present in 3/6 participants (50.0%) at 12 months.
Completed
| 2021 | Year | 04 | Month | 19 | Day |
| 2021 | Year | 04 | Month | 20 | Day |
| 2021 | Year | 06 | Month | 28 | Day |
| 2023 | Year | 02 | Month | 01 | Day |
| 2023 | Year | 02 | Month | 01 | Day |
| 2023 | Year | 02 | Month | 01 | Day |
| 2026 | Year | 11 | Month | 25 | Day |
| 2026 | Year | 11 | Month | 20 | Day |
| 2026 | Year | 11 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072851